(Q30976346)

27 June 2017

title

Metabolism of glucagon by dipeptidyl peptidase IV (CD26). (English)

1 reference

27 June 2017

1 reference

Pospisilik JA

1

1 reference

27 June 2017

Hinke SA

2

1 reference

27 June 2017

Pederson RA

3

1 reference

27 June 2017

Hoffmann T

4

1 reference

27 June 2017

Rosche F

5

1 reference

27 June 2017

Schlenzig D

6

1 reference

27 June 2017

Glund K

7

1 reference

27 June 2017

Heiser U

8

1 reference

27 June 2017

McIntosh CH

9

1 reference

27 June 2017

Demuth H

10

1 reference

27 June 2017

publication date

1 January 2001

1 reference

27 June 2017

1 reference

27 June 2017

volume

96

1 reference

27 June 2017

issue

3

1 reference

27 June 2017

page(s)

133-141

1 reference

The incretin notion and its relevance to diabetes.

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel [...]

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

The enteroinsular axis in dipeptidyl peptidase IV-negative rats

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Glucagon metabolism in man, studies on the metabolic clearance rate and the plasma acute disappearance time of glucagon in normal and diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Human dipeptidyl-peptidase I. Gene characterization, localization, and expression

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Kinetic Studies on Hepatic Handling of Glucagon Using the Model of Non-Recirculating Perfused Rat Livers

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Proline-dependent structural and biological properties of peptides and proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Dipeptidyl peptidase IV (DPP-IV) from pig kidney cleaves analogs of bovine growth hormone-releasing factor (bGRF) modified at position 2 with Ser, Thr or Val. Extended DPP-IV substrate specificity?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Structure-function relations in glucagon. Properties of highly purified Des-his1-, monoiodo-, and [Des-Asn28,Thr29](homoserine lactone27)-glucagon

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Regulated expression, processing, and secretion of dog mast cell dipeptidyl peptidase I.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Truncation of macrophage-derived chemokine by CD26/ dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Identification of a mammalian glutaminyl cyclase converting glutaminyl into pyroglutamyl peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

The degradation of bioactive peptides and proteins by dipeptidyl peptidase IV from human placenta

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Specific localization of membrane dipeptidase and dipeptidyl peptidase IV in secretion granules of two different pancreatic islet cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Stability of endogenous immunoreactive glucagon (IRG) in animal blood

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Glucagon: Structure-Function Relationships Investigated by Sequence Deletions

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

A synthetic glucagon-like peptide-1 analog with improved plasma stability

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Biological activity of GLP-1-analogues with N-terminal modifications

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2800%2900170-1

7 January 2021

10.1016/S0167-0115(00)00170-1

Identifiers

DOI

1 reference

27 June 2017

1 reference